Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash from Financing Activities (2019 - 2025)

Harmony Biosciences Holdings' Cash from Financing Activities history spans 7 years, with the latest figure at -$3.0 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 10.0% year-over-year to -$3.0 million; the TTM value through Dec 2025 reached -$9.0 million, up 17.71%, while the annual FY2025 figure was -$9.0 million, 17.71% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$3.0 million at Harmony Biosciences Holdings, down from -$3.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $7.1 million in Q4 2021 and bottomed at -$55.1 million in Q3 2023.
  • The 5-year median for Cash from Financing Activities is -$345500.0 (2023), against an average of -$5.6 million.
  • The largest annual shift saw Cash from Financing Activities soared 11425.0% in 2022 before it crashed 2787.76% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $7.1 million in 2021, then plummeted by 62.42% to $2.7 million in 2022, then plummeted by 2113.66% to -$53.5 million in 2023, then skyrocketed by 94.88% to -$2.7 million in 2024, then decreased by 10.0% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Cash from Financing Activities are -$3.0 million (Q4 2025), -$3.0 million (Q3 2025), and -$2.7 million (Q2 2025).